Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
Full description
Patients will receive three weeks of whole brain radiation therapy concurrent with daily motexafin gadolinium during weeks 2 and 3, followed by a stereotactic radiosurgery boost concurrent with motexafin gadolinium. Patients will be followed for radiologic response, neurologic progression, and neurocognitive progression.
Sex
Ages
Volunteers
Inclusion criteria
- Age ≥ 18 years
- Karnofsky performance status (KPS) ≥ 70
- Histologically confirmed malignancy with the presence of one to four intraparenchymal brain metastases
- Each patient must sign a study-specific Informed Consent form
Exclusion criteria
- Previous cranial radiation
- Complete resection of all known brain metastases
- Known leptomeningeal metastases
- Known liver metastases
- Clinical or radiologic evidence of progression (other than study lesion[s) within 1 month prior to enrollment
- Patients with metastases within 10 mm of the optic apparatus
- Patients with metastases in the brainstem, midbrain, pons, or medulla
- Planned chemotherapy during WBRT and/or SRS
- Uncontrolled hypertension
- Women who are pregnant or lactating
and Laboratory values as follows:
- LDH > 1.3 x upper limit of normal (ULN)
- ANC < 1500/mm3
- Platelets < 50,000/mm3
- Creatinine > 2.0 mg/dL
- AST or ALT > 3 x ULN
- Total bilirubin > 2 x ULN
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal